RAEB
MCID: MYL074
MIFTS: 38

Myelodysplastic Syndrome with Excess Blasts (RAEB)

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Myelodysplastic Syndrome with Excess Blasts

MalaCards integrated aliases for Myelodysplastic Syndrome with Excess Blasts:

Name: Myelodysplastic Syndrome with Excess Blasts 52
Refractory Anemia with Excess Blasts 52 58 17
Raeb 52 58

Characteristics:

Orphanet epidemiological data:

58
refractory anemia with excess blasts
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

MESH via Orphanet 44 D000754
ICD10 via Orphanet 33 D46.2
UMLS via Orphanet 72 C0002894
Orphanet 58 ORPHA86839

Summaries for Myelodysplastic Syndrome with Excess Blasts

NIH Rare Diseases : 52 Myelodysplastic syndrome with excess blasts is a rare type of myelodysplastic syndrome (MDS). In this type of MDS, the number of very early forms of blood cells (blasts) are increased in the bone marrow and/or blood. There is also a low numbers of at least one type of blood cell. The early forms of cell types in the bone marrow (red blood cells , white blood cells , or platelets ) may or may not look abnormal (dysplasia) under the microscope. Signs and symptoms may include a very hard to treat and persistent anemia (refractory anemia), frequent infections (due to low numbers of neutrophils), easy bruising and bleeding (due to low number or abnormal platelets). MDS with excess blasts is one of the MDS most likely to turn into acute myeloid leukemia (AML) . It is classified into 2 types, based on how many of the cells in the bone marrow or blood are blasts: MDS-EB1: blasts make up 5% to 9% of the cells in the bone marrow, or 2% to 4% of the cells in the blood MDS-EB2: blasts make up 10% to 19% of the cells in the bone marrow, or 5% to 19% of the cells in the blood; this type has a higher risk to become AML. Some cases of MDS are linked to known risk factors (such as smoking, chemotherapy , having a genetic syndrome that increases the chance of developing MDS and other). These factors lead to changes in the DNA in bone marrow cells may cause MDS to develop, but most often, the cause is unknown. Treatment may include blood transfusions, supportive care, chemotherapy, radiotherapy and bone marrow transplant . [ 14773]

MalaCards based summary : Myelodysplastic Syndrome with Excess Blasts, also known as refractory anemia with excess blasts, is related to aplastic anemia and refractory anemia with excess blasts type 2. An important gene associated with Myelodysplastic Syndrome with Excess Blasts is TET2 (Tet Methylcytosine Dioxygenase 2). The drugs Lenograstim and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are fatigue and anemia of inadequate production

Related Diseases for Myelodysplastic Syndrome with Excess Blasts

Diseases related to Myelodysplastic Syndrome with Excess Blasts via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 70, show less)
# Related Disease Score Top Affiliating Genes
1 aplastic anemia 29.4 TET2 LTA
2 refractory anemia with excess blasts type 2 12.9
3 refractory anemia with excess blasts type 1 12.8
4 refractory anemia with excess blasts in transformation 11.7
5 pancytopenia 10.5
6 myelodysplastic syndrome 10.5
7 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.4
8 deficiency anemia 10.4
9 refractory cytopenia with multilineage dysplasia 10.2
10 acute promyelocytic leukemia 10.2
11 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
12 leukemia 10.2
13 acute myeloblastic leukemia without maturation 10.2
14 erythroleukemia, familial 10.2
15 leukemia, acute myeloid 10.2
16 refractory anemia 10.2
17 mucositis 10.1
18 48,xyyy 10.1
19 chromosomal triplication 10.1
20 monosomy 22 10.1
21 familial mediterranean fever 10.1
22 severe cutaneous adverse reaction 10.1
23 graft-versus-host disease 10.1
24 leukemia, acute lymphoblastic 3 10.1
25 erythema multiforme 10.1
26 brucellosis 10.1
27 patau syndrome 10.1
28 nephrotic syndrome 10.1
29 ecthyma 10.1
30 thrombocytosis 10.1
31 macrocytic anemia 10.1
32 hyperglycemia 10.1
33 amyloidosis 10.1
34 polyarteritis nodosa 10.1
35 acute graft versus host disease 10.1
36 erythema multiforme major 10.1
37 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.1
38 precursor t-cell acute lymphoblastic leukemia 10.1
39 acute leukemia 10.1
40 myeloid leukemia 10.1
41 mixed phenotype acute leukemia 10.1
42 acute erythroid leukemia 10.1
43 aregenerative anemia 10.1
44 kaposi sarcoma 10.0
45 chromosome 5q deletion syndrome 10.0
46 hemophilia a 10.0
47 alpha-thalassemia 10.0
48 hemoglobin h disease 10.0
49 chronic myelomonocytic leukemia 10.0
50 thalassemia 10.0
51 neutropenia 10.0
52 toxic shock syndrome 10.0
53 thrombocytopenia 10.0
54 rectum cancer 10.0
55 thrombophlebitis 10.0
56 pyoderma 10.0
57 pneumonia 10.0
58 herpes zoster 10.0
59 pyoderma gangrenosum 10.0
60 vasculitis 10.0
61 chickenpox 10.0
62 sideroblastic anemia 10.0
63 mast-cell leukemia 10.0
64 exophthalmos 10.0
65 hemophilia 10.0
66 acute myeloblastic leukemia with maturation 10.0
67 ring chromosome 1 10.0
68 rapidly involuting congenital hemangioma 10.0
69 ring chromosome 10.0
70 leukemia, chronic lymphocytic 9.2 TET2 LTA

Graphical network of the top 20 diseases related to Myelodysplastic Syndrome with Excess Blasts:



Diseases related to Myelodysplastic Syndrome with Excess Blasts

Symptoms & Phenotypes for Myelodysplastic Syndrome with Excess Blasts

Human phenotypes related to Myelodysplastic Syndrome with Excess Blasts:

58 31 (showing 22, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
2 anemia of inadequate production 58 31 hallmark (90%) Very frequent (99-80%) HP:0010972
3 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
4 exertional dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002875
5 palpitations 58 31 frequent (33%) Frequent (79-30%) HP:0001962
6 anemic pallor 58 31 frequent (33%) Frequent (79-30%) HP:0001017
7 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
8 bone pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002653
9 pedal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0010741
10 retinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0000573
11 bone marrow hypocellularity 58 31 occasional (7.5%) Occasional (29-5%) HP:0005528
12 leukocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001974
13 acute myeloid leukemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0004808
14 chronic infection 58 31 occasional (7.5%) Occasional (29-5%) HP:0031035
15 dysplastic granulopoesis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012136
16 abnormal albumin level 58 31 occasional (7.5%) Occasional (29-5%) HP:0012116
17 multiple lineage myelodysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0012148
18 single lineage myelodysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0012150
19 abnormal mean corpuscular volume 58 31 occasional (7.5%) Occasional (29-5%) HP:0025065
20 abnormal bleeding 58 Occasional (29-5%)
21 abnormality of bone marrow cell morphology 58 Occasional (29-5%)
22 abnormality of circulating protein level 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Myelodysplastic Syndrome with Excess Blasts:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 8.62 LTA TET2

Drugs & Therapeutics for Myelodysplastic Syndrome with Excess Blasts

Drugs for Myelodysplastic Syndrome with Excess Blasts (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 176, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
2
Sargramostim Approved, Investigational Phase 2, Phase 3 83869-56-1, 123774-72-1
3
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
4
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 11096-26-7, 209810-58-2
5
Mercaptopurine Approved Phase 3 50-44-2 667490
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
8
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
9
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
10
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
11
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
12
Thioguanine Approved Phase 3 154-42-7 2723601
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
14
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
15
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
16
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
17
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
18
Hydroxyurea Approved Phase 3 127-07-1 3657
19
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
20
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
21
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
22
Ivosidenib Approved, Investigational Phase 3 1448347-49-6 71657455
23
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
24
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
25
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
26
Etoposide Approved Phase 3 33419-42-0 36462
27
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
28
Daunorubicin Approved Phase 3 20830-81-3 30323
29
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
30
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
31
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
32 Antilymphocyte Serum Phase 3
33 Hematinics Phase 3
34 Thymoglobulin Phase 3
35 Epoetin alfa Phase 2, Phase 3 113427-24-0
36 Pharmaceutical Solutions Phase 2, Phase 3
37 Antineoplastic Agents, Immunological Phase 2, Phase 3
38 Adjuvants, Immunologic Phase 3
39 Alkylating Agents Phase 2, Phase 3
40 Antirheumatic Agents Phase 3
41 Gemtuzumab Phase 3
42 Analgesics Phase 3
43 Antineoplastic Agents, Hormonal Phase 3
44 Keratolytic Agents Phase 3
45 Hydrocortisone 17-butyrate 21-propionate Phase 3
46 Hydrocortisone-17-butyrate Phase 3
47 Hydrocortisone hemisuccinate Phase 3
48
asparaginase Phase 3
49 Neurotransmitter Agents Phase 3
50 Immunosuppressive Agents Phase 3
51 Immunologic Factors Phase 3
52 Antimetabolites Phase 3
53 Antibiotics, Antitubercular Phase 3
54 Anti-Infective Agents Phase 3
55 Antiviral Agents Phase 3
56 Anti-Bacterial Agents Phase 3
57 Protein Kinase Inhibitors Phase 3
58 ON 01910 Phase 3
59 Etoposide phosphate Phase 3
60
Ciprofloxacin Approved, Investigational Phase 2 85721-33-1 2764
61
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
62
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
63
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
64
Etanercept Approved, Investigational Phase 2 185243-69-0
65
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141
66
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
67
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
68
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
69
Infliximab Approved Phase 2 170277-31-3
70
Bexarotene Approved, Investigational Phase 2 153559-49-0 82146
71
Tocopherol Approved, Investigational Phase 1, Phase 2 1406-66-2, 54-28-4 14986
72
Isotretinoin Approved Phase 1, Phase 2 4759-48-2 5282379 5538
73
Adenosine Approved, Investigational Phase 2 58-61-7 60961
74
Methoxsalen Approved Phase 2 298-81-7 4114
75
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693 40926
76
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
77
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
78
Mycophenolic acid Approved Phase 2 24280-93-1 446541
79
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
80
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
81
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
82
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
83 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
84
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
85
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
86
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
87
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
88
Mesna Approved, Investigational Phase 2 3375-50-6 598
89
Carmustine Approved, Investigational Phase 2 154-93-8 2578
90
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
91
Allopurinol Approved Phase 2 315-30-0 2094
92
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
93
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
94
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-02-9 14985
95
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
96
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
97 10-hydroxycamptothecin Investigational Phase 2 19685-09-7
98 Bryostatin 1 Investigational Phase 2 83314-01-6
99
Vatalanib Investigational Phase 2 212141-54-3 151194
100 Tocotrienol Investigational Phase 1, Phase 2 6829-55-6
101
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
102 Freund's Adjuvant Phase 2
103 BB 1101 Phase 2
104 Citrate Phase 1, Phase 2
105 Semaxinib Phase 1, Phase 2
106 topoisomerase I inhibitors Phase 2
107 Analgesics, Non-Narcotic Phase 2
108 Anti-Inflammatory Agents, Non-Steroidal Phase 2
109 Radiation-Protective Agents Phase 1, Phase 2
110 Endothelial Growth Factors Phase 2
111 Antacids Phase 1, Phase 2
112 Anti-Ulcer Agents Phase 1, Phase 2
113
Bismuth Phase 1, Phase 2 7440-69-9 16682734 105143
114 Immunoglobulins, Intravenous Phase 2
115 Rho(D) Immune Globulin Phase 2
116 gamma-Globulins Phase 2
117 2-chloro-3'-deoxyadenosine Phase 2
118 Antioxidants Phase 1, Phase 2
119 Tocotrienols Phase 1, Phase 2
120 Tocopherols Phase 1, Phase 2
121 Furocoumarins Phase 2
122 Photosensitizing Agents Phase 2
123 Angiogenesis Inhibitors Phase 1, Phase 2
124 Antitubercular Agents Phase 2
125 Gastrointestinal Agents Phase 2
126 Anti-Inflammatory Agents Phase 2
127 Protective Agents Phase 2
128 Methylprednisolone Acetate Phase 2
129 Hormones Phase 2
130 Antiemetics Phase 2
131 Hormone Antagonists Phase 2
132 glucocorticoids Phase 2
133 Neuroprotective Agents Phase 2
134 Mitogens Phase 2
135 Histone Deacetylase Inhibitors Phase 2
136 Micronutrients Phase 2
137 Trace Elements Phase 2
138 Vitamins Phase 2
139 Antidotes Phase 2
140 Nutrients Phase 2
141 Calcium, Dietary Phase 2
142 Calciferol Phase 2
143 diuretics Phase 2
144
Calcium Nutraceutical Phase 2 7440-70-2 271
145
Aldesleukin Approved Phase 1 85898-30-2, 110942-02-4
146
Vincristine Approved, Investigational Phase 1 57-22-7, 2068-78-2 5978
147
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
148
Prednisone Approved, Vet_approved Phase 1 53-03-2 5865
149
rituximab Approved Phase 1 174722-31-7 10201696
150
Panitumumab Approved, Investigational Phase 1 339177-26-3 50070211
151
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 43805 6857599 5310940 9887054
152
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
153
tannic acid Approved Phase 1 1401-55-4
154
Benzocaine Approved, Investigational Phase 1 94-09-7, 1994-09-7 2337